Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)
Mayo Clinic
Summary
This study assesses if metastasis-directed radiation therapy (Stereotactic body radiation therapy - SBRT) can delay a change in systemic therapy, and if circulating tumor cells in the bloodstream can help guide treatment options in metastatic breast cancer patients with progressive disease
Eligibility
- Age range
- 18+ years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * Age ≥ 18 years. * Histological confirmation of primary breast cancer. * Patients with metastatic breast cancer and at least 12 months of clinical response to first-line systemic therapy, with the subsequent development of 1-3 extracranial sites of oligoprogressive disease, and who plan for the continuation of the current systemic therapy. * NOTE: patients with de novo metastatic disease and those developed metastatic disease after initially localized disease can both be included. OR * Patients with metastatic breast cancer and at least 6 months of clinical response…
Interventions
- ProcedureBiospecimen Collection
Undergo blood sample collection
- OtherSurveys
Patients complete the European Quality of Life 5 Dimensions 5 Level Version (EQ-5D-5L) survey and "Was it Worth It" questionnaire.
- RadiationStereotactic Body Radiation Therapy (SBRT)
Patients receive stereotactic body radiation therapy (SBRT), metastasis-directed radiation therapy .
- ProcedureComputed Tomography
Undergo CT, MRI and/or PET/CT
- ProcedureMagnetic Resonance Imaging
Undergo CT, MRI and/or PET/CT
- ProcedurePositron Emission Tomography
Undergo CT, MRI and/or PET/CT
Locations (2)
- Mayo Clinic in ArizonaScottsdale, Arizona
- Mayo Clinic in RochesterRochester, Minnesota